Lopez-Beltran Antonio, Blanca Ana, Cimadamore Alessia, Gogna Rajan, Montironi Rodolfo, Cheng Liang
Department of Morphological Sciences, University of Cordoba Medical School, E-14004 Cordoba, Spain.
Maimonides Biomedical Research Institute of Cordoba, Department of Urology, University Hospital of Reina Sofia, E-14004 Cordoba, Spain.
Cancers (Basel). 2021 Nov 1;13(21):5500. doi: 10.3390/cancers13215500.
Molecular classification of bladder carcinoma is a relevant topic in modern bladder cancer oncology due to its potential to improve oncological outcomes. The available molecular classifications are generally based on transcriptomic profiles, generating highly diverse categories with limited correlation. Implementation of molecular classification in practice is typically limited due to the high complexity of the required technology, the elevated costs, and the limited availability of this technology worldwide. We have conducted a gene expression analysis using a four-gene panel related to luminal and basal subtypes in a series of 91 bladder cancer cases. NanoString-based gene expression analysis using typically luminal (GATA3+/KRT20+) and basal markers (KRT14+/KRT5+/GATA3low/-/KRT20low/-) classified urothelial bladder carcinoma samples as luminal, basal, and a third category (KRT14-/KRT5-/GATA3-/KRT20-), null/double negative (non-luminal/non-basal). These three categories were meaningful in terms of overall cancer-specific survival ( < 0.0001) or when classified as conventional urothelial carcinoma and variant histology urothelial carcinoma ( < 0.0001), NMIBC vs. MIBC ( < 0.001), or by AJCC stage category Ta ( = 0.0012) and T1 ( < 0.0001) but did not reach significance in T2-T4 ( = 0.563). PD-L1 expression (low vs. high) was also different according to molecular subtype, with high PD-L1 expression mostly seen in basal and null subtypes and carcinomas with variant histology ( = 0.002). Additionally, the luminal subtype was enriched in NMIBC with favorable cancer-specific survival ( < 0.0001). In contrast, basal and null subtypes resulted in aggressive MIBC tumors with shorter cancer-specific survival ( < 0.0001), some of which presented variant histology. In conclusion, a comprehensive evaluation of a gene classifier related to molecular taxonomy using NanoString technology is feasible. Therefore, it might represent an accessible and affordable tool in this rapidly expanding area of precision genomics.
膀胱癌的分子分类是现代膀胱癌肿瘤学中的一个重要课题,因为它有可能改善肿瘤治疗效果。现有的分子分类通常基于转录组图谱,产生的类别高度多样且相关性有限。由于所需技术的高度复杂性、成本高昂以及该技术在全球范围内的可用性有限,分子分类在实践中的应用通常受到限制。我们使用与腔面和基底亚型相关的四基因面板,对91例膀胱癌病例进行了基因表达分析。基于NanoString的基因表达分析使用典型的腔面标志物(GATA3+/KRT20+)和基底标志物(KRT14+/KRT5+/GATA3low/-/KRT20low/-),将尿路上皮膀胱癌样本分为腔面型、基底型和第三类(KRT14-/KRT5-/GATA3-/KRT20-),即无/双阴性(非腔面/非基底)。这三类在总体癌症特异性生存方面具有显著意义(<0.0001),或者在分类为传统尿路上皮癌和变异组织学尿路上皮癌时具有显著意义(<0.0001),非肌层浸润性膀胱癌(NMIBC)与肌层浸润性膀胱癌(MIBC)相比具有显著意义(<0.001),或者按美国癌症联合委员会(AJCC)分期类别Ta(=0.0012)和T1(<0.0001)分类时具有显著意义,但在T2 - T4期未达到显著意义(=0.563)。PD-L1表达(低表达与高表达)也因分子亚型而异,高PD-L1表达主要见于基底型和无/双阴性亚型以及具有变异组织学的癌(=0.002)。此外,腔面型在NMIBC中富集,具有良好的癌症特异性生存(<0.0001)。相比之下,基底型和无/双阴性亚型导致侵袭性MIBC肿瘤,癌症特异性生存较短(<0.0001),其中一些表现为变异组织学。总之,使用NanoString技术对与分子分类学相关的基因分类器进行全面评估是可行的。因此,它可能是这个快速发展的精准基因组学领域中一种易于获取且经济实惠的工具。